BOSTON, April 04, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Applications (NDAs) and granted a priority review for omadacycline, an…Original Article
Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
